TY  - PAT
AU  - Marković, Maja
AU  - Tadić, Julijana
AU  - Šešlija, Sanja
AU  - Mijin, Dušan
AU  - Panić, Vesna
AU  - Spasojević, Pavle
AU  - Pjanović, Rada
AU  - Ugrinović, Vukašin
PY  - 2023
UR  - http://pub.zis.gov.rs/rs-pubserver/document?iDocId=103007&iepatch=.pdf
UR  - https://hdl.handle.net/21.15107/rcub_technorep_5950
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/6138
AB  - Predmetnim pronalaskom postignuta je inkapsulacija slabo vodorastvorne aktivne supstance heterocikličnog azo jedinjenja sa antikancerogenim svojstvima u hidrofilni hidrogel na bazi poli(metakrilne kiseline) modifikovanog amfifilnim kazeinom, ciljana dostava inkapsuliranog azo derivata i njegovo kontrolisano i produženo otpuštanje (i do 72h) bez naglog inicijalnog oslobadanja iz hidrofilnog hidrogela. Takođe, predmetnim pronalaskom su dobijeni nosači koji bi imali potencijalnu primenu u tretmanu hronične mijeloidne leukemije (HML), čijom bi se primenom smanjio broj potrebnih terapeutskih doza i redukovali neželjeni efekti (kao što je povraćanje i iritacija gastrointestinalnog trakta) koji se najčešće javljaju kod primene lekova za terapiju HML.
PB  - Beograd, Srbija : Zavod za intelektualnu svojinu
T2  - Republika Srbija - Patentni spis
T1  - Sistem na bazi poli (metakrilne kiseline) i kazeina za kontrolisano otpuštanje heterocikličnog azo jedinjenja sa potencijalnom primenom u tretmanu malignog oboljenja belih krvnih ćelija
SP  - RS 63926
UR  - https://hdl.handle.net/21.15107/rcub_cer_6138
ER  - 

@misc{
author = "Marković, Maja and Tadić, Julijana and Šešlija, Sanja and Mijin, Dušan and Panić, Vesna and Spasojević, Pavle and Pjanović, Rada and Ugrinović, Vukašin",
year = "2023",
abstract = "Predmetnim pronalaskom postignuta je inkapsulacija slabo vodorastvorne aktivne supstance heterocikličnog azo jedinjenja sa antikancerogenim svojstvima u hidrofilni hidrogel na bazi poli(metakrilne kiseline) modifikovanog amfifilnim kazeinom, ciljana dostava inkapsuliranog azo derivata i njegovo kontrolisano i produženo otpuštanje (i do 72h) bez naglog inicijalnog oslobadanja iz hidrofilnog hidrogela. Takođe, predmetnim pronalaskom su dobijeni nosači koji bi imali potencijalnu primenu u tretmanu hronične mijeloidne leukemije (HML), čijom bi se primenom smanjio broj potrebnih terapeutskih doza i redukovali neželjeni efekti (kao što je povraćanje i iritacija gastrointestinalnog trakta) koji se najčešće javljaju kod primene lekova za terapiju HML.",
publisher = "Beograd, Srbija : Zavod za intelektualnu svojinu",
journal = "Republika Srbija - Patentni spis",
title = "Sistem na bazi poli (metakrilne kiseline) i kazeina za kontrolisano otpuštanje heterocikličnog azo jedinjenja sa potencijalnom primenom u tretmanu malignog oboljenja belih krvnih ćelija",
pages = "RS 63926",
url = "https://hdl.handle.net/21.15107/rcub_cer_6138"
}

Marković, M., Tadić, J., Šešlija, S., Mijin, D., Panić, V., Spasojević, P., Pjanović, R.,& Ugrinović, V.. (2023). Sistem na bazi poli (metakrilne kiseline) i kazeina za kontrolisano otpuštanje heterocikličnog azo jedinjenja sa potencijalnom primenom u tretmanu malignog oboljenja belih krvnih ćelija. in Republika Srbija - Patentni spis
Beograd, Srbija : Zavod za intelektualnu svojinu., RS 63926.
https://hdl.handle.net/21.15107/rcub_cer_6138

Marković M, Tadić J, Šešlija S, Mijin D, Panić V, Spasojević P, Pjanović R, Ugrinović V. Sistem na bazi poli (metakrilne kiseline) i kazeina za kontrolisano otpuštanje heterocikličnog azo jedinjenja sa potencijalnom primenom u tretmanu malignog oboljenja belih krvnih ćelija. in Republika Srbija - Patentni spis. 2023;:RS 63926.
https://hdl.handle.net/21.15107/rcub_cer_6138 .

Marković, Maja, Tadić, Julijana, Šešlija, Sanja, Mijin, Dušan, Panić, Vesna, Spasojević, Pavle, Pjanović, Rada, Ugrinović, Vukašin, "Sistem na bazi poli (metakrilne kiseline) i kazeina za kontrolisano otpuštanje heterocikličnog azo jedinjenja sa potencijalnom primenom u tretmanu malignog oboljenja belih krvnih ćelija" in Republika Srbija - Patentni spis (2023):RS 63926,
https://hdl.handle.net/21.15107/rcub_cer_6138 .

TY  - JOUR
AU  - Marković, Maja D.
AU  - Tadić, Julijana D.
AU  - Savić, Sanja I.
AU  - Matić, Ivana Z.
AU  - Stanojković, Tatjana
AU  - Mijin, Dušan
AU  - Panić, Vesna
PY  - 2022
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/5429
AB  - Researchers are faced with everyday demands for safer and more efficient therapy for many diseases, especially serious one such as various types of cancer. Numerous anticancer drugs are poorly-water soluble and therefore their encapsulation and controlled release remain quite challenge. In present study, we deepened our research of hydrophilic carrier based on poly(methacrylic acid) and casein (PMAC) by investigating its potential for encapsulation and controlled release of novel poorly water-soluble dihydropyrimidion-azo-pyridon compound (DHPMP). DHPMP is a dye that has been proven to show cytotoxic activity against chronic myeloid leukemia K562 cells. By encapsulating DHPMP into the carrier and delivering it into the intestines, DHPMP absorption could be the fastest and the number of therapeutic doses and side effects can be reduced. Carriers based on PMAC and DHPMP (PMAC-DHPMP) were synthetized and characterized by FTIR, SEM and single compression tests. The swelling behavior of PMAC-DHPMP carriers and cumulative DHPMP release were investigated depending on the amount of crosslinker and encapsulated DHPMP in two media which were simulating pH environments in human stomach and intestines. The prolonged and controlled release of DHPMP was achieved. In vitro cytotoxic activity of PMAC-DHPMP carriers against K562 cells and the cell cycle analysis showed great potential of the carriers for application in leukemia treatment.
PB  - Wiley
T2  - Journal of Biomedical Materials Research - Part A
T1  - Soft 3D hybrid network for delivery and controlled release of poorly soluble dihydropyrimidinone compound: An insight into the novel system for potential application in leukemia treatment
VL  - 110
IS  - 9
SP  - 1564
EP  - 1578
DO  - 10.1002/jbm.a.37396
ER  - 

@article{
author = "Marković, Maja D. and Tadić, Julijana D. and Savić, Sanja I. and Matić, Ivana Z. and Stanojković, Tatjana and Mijin, Dušan and Panić, Vesna",
year = "2022",
abstract = "Researchers are faced with everyday demands for safer and more efficient therapy for many diseases, especially serious one such as various types of cancer. Numerous anticancer drugs are poorly-water soluble and therefore their encapsulation and controlled release remain quite challenge. In present study, we deepened our research of hydrophilic carrier based on poly(methacrylic acid) and casein (PMAC) by investigating its potential for encapsulation and controlled release of novel poorly water-soluble dihydropyrimidion-azo-pyridon compound (DHPMP). DHPMP is a dye that has been proven to show cytotoxic activity against chronic myeloid leukemia K562 cells. By encapsulating DHPMP into the carrier and delivering it into the intestines, DHPMP absorption could be the fastest and the number of therapeutic doses and side effects can be reduced. Carriers based on PMAC and DHPMP (PMAC-DHPMP) were synthetized and characterized by FTIR, SEM and single compression tests. The swelling behavior of PMAC-DHPMP carriers and cumulative DHPMP release were investigated depending on the amount of crosslinker and encapsulated DHPMP in two media which were simulating pH environments in human stomach and intestines. The prolonged and controlled release of DHPMP was achieved. In vitro cytotoxic activity of PMAC-DHPMP carriers against K562 cells and the cell cycle analysis showed great potential of the carriers for application in leukemia treatment.",
publisher = "Wiley",
journal = "Journal of Biomedical Materials Research - Part A",
title = "Soft 3D hybrid network for delivery and controlled release of poorly soluble dihydropyrimidinone compound: An insight into the novel system for potential application in leukemia treatment",
volume = "110",
number = "9",
pages = "1564-1578",
doi = "10.1002/jbm.a.37396"
}

Marković, M. D., Tadić, J. D., Savić, S. I., Matić, I. Z., Stanojković, T., Mijin, D.,& Panić, V.. (2022). Soft 3D hybrid network for delivery and controlled release of poorly soluble dihydropyrimidinone compound: An insight into the novel system for potential application in leukemia treatment. in Journal of Biomedical Materials Research - Part A
Wiley., 110(9), 1564-1578.
https://doi.org/10.1002/jbm.a.37396

Marković MD, Tadić JD, Savić SI, Matić IZ, Stanojković T, Mijin D, Panić V. Soft 3D hybrid network for delivery and controlled release of poorly soluble dihydropyrimidinone compound: An insight into the novel system for potential application in leukemia treatment. in Journal of Biomedical Materials Research - Part A. 2022;110(9):1564-1578.
doi:10.1002/jbm.a.37396 .

Marković, Maja D., Tadić, Julijana D., Savić, Sanja I., Matić, Ivana Z., Stanojković, Tatjana, Mijin, Dušan, Panić, Vesna, "Soft 3D hybrid network for delivery and controlled release of poorly soluble dihydropyrimidinone compound: An insight into the novel system for potential application in leukemia treatment" in Journal of Biomedical Materials Research - Part A, 110, no. 9 (2022):1564-1578,
https://doi.org/10.1002/jbm.a.37396 . .

TY  - JOUR
AU  - Tadić, Julijana D.
AU  - Lađarević, Jelena
AU  - Vitnik, Željko
AU  - Vitnik, Vesna
AU  - Stanojković, Tatjana
AU  - Matić, Ivana Z.
AU  - Mijin, Dušan
PY  - 2021
UR  - https://cer.ihtm.bg.ac.rs/handle/123456789/4172
AB  - Seven novel azo dyes with 2-pyridone and dihydropyrimidinone moieties have been synthesized and thoroughly characterized. The azo-hydrazone tautomerism 		has been investigated by experimental and theoretical approaches. The optimizations of geometries have been performed with density functional theory (DFT). 		The vibrational and NMR spectra were calculated and correlated with experimental ones. Furthermore, quantum chemical descriptors were calculated and MEP 		maps were plotted to determine biological reactivity of dyes. The antioxidant assay evinced that 5, 6 and 7 are promising antioxidant candidates. In vitro 			cytotoxic activity was studied against three malignant cell lines: prostate adenocarcinoma (PC-3), lung carcinoma (A549) and chronic myelogenous leukemia 			(K562), as well as against human normal lung fibroblasts (MRC-5), using MTT assay. Examination of cytotoxic effects on human cancer cell lines showed the 		concentration dependent cytotoxicity of all investigated compounds. The K562 cells were the most sensitive to the cytotoxicity of the compounds 3, 5 and 6, 		wherein compound 5 was particularly prominent and selective in cytotoxic action between K562 (24.97 μM) and PC-3 (48.98 μM) cancer cells, and normal 			MRC-5 (91.11 μM) cells. Moreover, the cell cycle analysis of compound 5 was examined in K562 cells, by flow cytometry, to study its mechanism 				of anticancer action. Finally, in silico evaluation of physicochemical parameters, druglikeness and ADME properties showed that investigated compounds are 		orally bioavailable with no permeation to the blood brain barrier.
PB  - Elsevier
T2  - Dyes and Pigments
T1  - Novel azo pyridone dyes based on dihydropyrimidinone skeleton: Synthesis, DFT study and anticancer activity
VL  - 187
SP  - 109123
DO  - 10.1016/j.dyepig.2020.109123
ER  - 

@article{
author = "Tadić, Julijana D. and Lađarević, Jelena and Vitnik, Željko and Vitnik, Vesna and Stanojković, Tatjana and Matić, Ivana Z. and Mijin, Dušan",
year = "2021",
abstract = "Seven novel azo dyes with 2-pyridone and dihydropyrimidinone moieties have been synthesized and thoroughly characterized. The azo-hydrazone tautomerism 		has been investigated by experimental and theoretical approaches. The optimizations of geometries have been performed with density functional theory (DFT). 		The vibrational and NMR spectra were calculated and correlated with experimental ones. Furthermore, quantum chemical descriptors were calculated and MEP 		maps were plotted to determine biological reactivity of dyes. The antioxidant assay evinced that 5, 6 and 7 are promising antioxidant candidates. In vitro 			cytotoxic activity was studied against three malignant cell lines: prostate adenocarcinoma (PC-3), lung carcinoma (A549) and chronic myelogenous leukemia 			(K562), as well as against human normal lung fibroblasts (MRC-5), using MTT assay. Examination of cytotoxic effects on human cancer cell lines showed the 		concentration dependent cytotoxicity of all investigated compounds. The K562 cells were the most sensitive to the cytotoxicity of the compounds 3, 5 and 6, 		wherein compound 5 was particularly prominent and selective in cytotoxic action between K562 (24.97 μM) and PC-3 (48.98 μM) cancer cells, and normal 			MRC-5 (91.11 μM) cells. Moreover, the cell cycle analysis of compound 5 was examined in K562 cells, by flow cytometry, to study its mechanism 				of anticancer action. Finally, in silico evaluation of physicochemical parameters, druglikeness and ADME properties showed that investigated compounds are 		orally bioavailable with no permeation to the blood brain barrier.",
publisher = "Elsevier",
journal = "Dyes and Pigments",
title = "Novel azo pyridone dyes based on dihydropyrimidinone skeleton: Synthesis, DFT study and anticancer activity",
volume = "187",
pages = "109123",
doi = "10.1016/j.dyepig.2020.109123"
}

Tadić, J. D., Lađarević, J., Vitnik, Ž., Vitnik, V., Stanojković, T., Matić, I. Z.,& Mijin, D.. (2021). Novel azo pyridone dyes based on dihydropyrimidinone skeleton: Synthesis, DFT study and anticancer activity. in Dyes and Pigments
Elsevier., 187, 109123.
https://doi.org/10.1016/j.dyepig.2020.109123

Tadić JD, Lađarević J, Vitnik Ž, Vitnik V, Stanojković T, Matić IZ, Mijin D. Novel azo pyridone dyes based on dihydropyrimidinone skeleton: Synthesis, DFT study and anticancer activity. in Dyes and Pigments. 2021;187:109123.
doi:10.1016/j.dyepig.2020.109123 .

Tadić, Julijana D., Lađarević, Jelena, Vitnik, Željko, Vitnik, Vesna, Stanojković, Tatjana, Matić, Ivana Z., Mijin, Dušan, "Novel azo pyridone dyes based on dihydropyrimidinone skeleton: Synthesis, DFT study and anticancer activity" in Dyes and Pigments, 187 (2021):109123,
https://doi.org/10.1016/j.dyepig.2020.109123 . .